Age: 63.0
Sex: F
Vaccine: VARZOS, VARZOS
Symptoms: Arthralgia, Condition aggravated, Depression, Fatigue, Hair growth abnormal
Clinical narrative: hands and legs weakness; depression; blurry vision; urinary frequency; unexpected benefit: growing head hair; headache; fatigue; peeling right pinky-ring-middle fingers/finger peeling; worsened rheumatoid arthritis; chickenpox; severe joint pain/ experienced joint pain; This case was reported by a consumer via call center representative and described the occurrence of rheumatoid arthritis aggravated in a 63-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included eosinophilia. Concurrent medical conditions included asthma, chronic rhinosinusitis with nasal polyps, alopecia, autoimmune disorder and rheumatoid arthritis. Concomitant products included RECOMBINANT VARICELLA ZOSTER VIRUS SURFACE GLYCOPROTEIN E (SHINGRIX), mepolizumab (Nucala), steroids nos (Steroids), acetylsalicylic acid (Aspirin), etanercept (Embrel) and methotrexate.   On 22nd May 2022, the patient received the 2nd dose of Shingrix. On 30th May 2022, 8 days after receiving Shingrix, the patient experienced rheumatoid arthritis aggravated (serious criteria GSK medically significant), chickenpox and joint pain. On 2nd June 2022, the patient experienced skin peeling. On 19th June 2022, the patient experienced headache and fatigue. On 27th June 2022, the patient experienced hair growth increased. On 19th July 2022, the patient experienced muscle weakness, depression, blurred vision and urinary frequency. On an unknown date, the outcome of the rheumatoid arthritis aggravated, chickenpox, joint pain, headache, fatigue, skin peeling, muscle weakness, depression, blurred vision and urinary frequency were recovered/resolved and the outcome of the hair growth increased was unknown.   It was unknown if the reporter considered the rheumatoid arthritis aggravated, chickenpox, joint pain, headache, fatigue, skin peeling, hair growth increased, muscle weakness, depression, blurred vision and urinary frequency to be related to Shingrix.     Linked case(s) involving the same patient:  US2022119620, US2022AMR120632   Additional Information: GSK Receipt Date: 17-AUG-2022 Reporter's Comments: The consumer reported that patient received her first 1st doses of Shingrix on 21st March 2022.  The patient received her second of 2nd doses of Shingrix on 22nd May 2022 and experienced joint pain, worsened rheumatoid arthritis, and had chickenpox within a week of the second injection and all symptoms had resolved. 11 days after receiving shingrix patient experienced skin peeling. 28 days after receiving shingrix patient experienced headache and fatigue. 36 days after receiving shingrix patient experienced hair growth increased. 58 days after receiving shingrix patient experienced muscle weakness, depression, blurred vision and urinary frequency. The vaccine administration facility was the same as Primary Reporter. The lot numbers and expiration dates unknown for Shingrix. The reporter consent to follow up. The case had been linked with US2022119620, US2022AMR120632 reported by same reporter for same patient. Note: As per onset date TTO was captured however reactionfirsttime value does not match which auto calculated TTO clarification was raised for same.; Sender's Comments:  US-GSK-US2022AMR120632:Same reporter, same patient